153710 — Optipharm Co Income Statement
0.000.00%
Last trade - 00:00- KR₩77bn
- KR₩74bn
- KR₩20bn
- 34
- 12
- 29
- 11
Annual income statement for Optipharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 13,046 | 14,258 | 16,008 | 17,373 | 19,636 |
| Cost of Revenue | |||||
| Gross Profit | 3,509 | 3,738 | 3,717 | 4,197 | 4,897 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 16,499 | 18,763 | 19,385 | 20,004 | 22,088 |
| Operating Profit | -3,454 | -4,505 | -3,377 | -2,631 | -2,452 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2,352 | -3,080 | -2,045 | -2,437 | -2,357 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2,352 | -3,080 | -2,045 | -2,437 | -2,357 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2,352 | -3,080 | -2,045 | -2,437 | -2,357 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2,352 | -3,080 | -2,045 | -2,437 | -2,357 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -164 | -211 | -140 | -166 | -161 |
| Dividends per Share |